At a Glance
AI-generatedEvofem Biosciences, Inc.
8-K
Evofem Biosciences, Inc. and Windtree Therapeutics, Inc. entered into a Termination Agreement on March 13, 2026, mutually terminating their License and Supply Agreement (originally dated March 20, 2025, and amended) with no termination fees payable. Certain customary survival provisions of the original agreement remain in effect, and Windtree must cease using the company's IP and return confidential information.—
Market Cap
—
Revenue
—
Net Income
Employees32
Fundamentals
How The Business Makes Money
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001618835
ISINUS30048L3024
CUSIP30048L104
Phone858 550 1900
Address12400 High Bluff Drive, San Diego, CA, 92130, US
SEC EDGAR